SLC5A2 and diabetic kidney disease: In recent years, new therapeutic options for DKD have evolved, such as SGLT-2 inhibitors, DPP-4 inhibitors and GLP-1 receptor agonists, and the incidence of DKD and associated vascular complications continue to increase [3,4,5].